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Background: Acceleration of skin regeneration is still an unsolved problem in the clinical 
treatment of patients suffering from deep burns and scalds. Although erythropoietin (EPO) has 
a protective role in a wide range of organs and cells during ischemia and after trauma, it has 
been recently discovered that EPO is not tissue-protective in the common β subunit receptor 
(βCR) knockout mouse. The protective capacity of EPO in tissue is mediated via a heterorecep-
tor complex comprising both the erythropoietin receptor (EPOR) and βCR. However, proof of 
coexpression of these heterogenic receptors in regenerating skin after burns is still lacking.
Methods: To understand the role of nanosized recombinant human erythropoietin (rhEPO) in 
wound healing, we investigated the effects of subcutaneous injections of EPO on skin regenera-
tion after deep second-degree scalding injuries. Our aim was to determine if joint expression 
of EPOR and βCR is a prerequisite for the tissue-protective effect of rhEPO. The efficiency in 
wound regeneration in a skin scalding injury mouse model was examined. A deep second-degree 
dermal scald injury was produced on the backs of 20 female Balb/c mice which were subse-
quently randomized to four experimental groups, two of which received daily subcutaneous 
injections of rhEPO. At days 7 and 14, the mice were sacrificed and the effects of rhEPO were 
analyzed with respect to grade of re-epithelialization (wound closure) and stage of epidermal 
maturation. This was investigated using different histological parameters of epithelial covering, 
such as depth of the epidermal layer, epidermal stratification, and presence of conical and hair 
follicle structures.
Results: Expression of EPOR, βCR, and growth hormone receptor at the mRNA and protein 
levels was demonstrated with reverse transcriptase polymerase chain reaction and Western blot 
analysis. After rhEPO treatment, the rate of re-epithelialization of the scalding injury was 
increased and the time to final wound closure was reduced. In addition, the quality of regener-
ated skin was improved. In this investigation, for the first time, we demonstrated coexpression 
of EPOR and βCR at the RNA and protein levels in vivo using a deep second-degree scalding 
injury mouse model. These results highlight the potential role of rhEPO in the improved   treatment 
of burns patients, which might be crucial for the development of innovative new therapy 
regimes.
Conclusion: Local injection of nanosized rhEPO directly to the injury site rather than systemic 
administration for deep second-degree scalding injuries achieved complete skin regeneration 
with conical and hair follicle structure via combined expression of EPOR and βCR.
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Introduction
Despite modern intensive care for burns patients, there has 
been no significant improvement of complete skin regenera-
tion with conical and hair follicle structure. The delayed 
healing process associated with large, deep thermal dermal 
injuries is often accompanied by complications, such as 
infections and sepsis; pulmonary, hepatic, or renal failure; 
loss of bone and muscle mass; poor wound healing; and 
hormonal imbalance.1 Just recently, Avni et al2 reviewed 
topical antibiotic application in burns and concluded that 
there were no beneficial effects. In contrast with topical 
application of other growth factors used clinically for wound 
care, recombinant human erythropoietin (rhEPO) plays an 
important role in revascularization during the early and late 
stages of injury and increases the capillary density in dam-
aged wound areas. In recent years, several studies have been 
conducted in which rhEPO was used successfully to stimulate 
angiogenesis and enhance wound healing, for example, by 
systemic application in both normal and genetically diabetic 
mice,3,4 via topical treatment in a diabetic rat model,5 and in 
our previous study of acute and chronic wounds in humans.6 
Moreover, a number of studies have reported that rhEPO 
affects the proliferation and differentiation of erythroid 
progenitor cells in hematopoietic organs, as well as nonhe-
matopoietic cell types and organs, and plays a central role 
in tissue protection.7–11
Although these reports have had encouraging outcomes, 
the lack of proof of common β subunit receptor (βCR) expres-
sion as the relevant tissue-based target for rhEPO in wound 
repair has been an important but missing link to explain the 
success of rhEPO in skin wound regeneration. In contrast 
with the homodimer hematopoietic EPO receptor (EPOR),12 
the tissue protective receptor is postulated to be a heterodimer 
formed by the EPO receptor in assembly with the βCR sub-
unit, otherwise known as CD131, which is also used by other 
type I cytokines.
In 2004, Brines et al10 found that EPOR and βCR in 
nonhematopoietic cells together comprise a tissue-protective 
heteroreceptor as components of receptor-mediated tissue 
protection instead of only EPOR in the case of cardiac 
trauma. They evaluated the cytoprotective role of βCR in 
cardiomyocytes isolated from βCR knockout mice and found 
that, although there was an adequate presence of EPOR, it 
was not sufficient to achieve a cytoprotective effect for 
rhEPO, suggesting that βCR has a vital role in tissue protec-
tion to reduce the potential for apoptosis. Further, it has been 
demonstrated that the heterodimer (EPOR and βCR) is not 
needed for erythropoiesis in βCR knockout mice; a normal 
erythropoietic response to rhEPO is existing although these 
mice lack the heterodimer.13
The tissue-protective role of EPO in skin regeneration 
has not yet been examined fully.
In 2007, LeBaron et al14 demonstrated that hair follicle 
dermal papilla fibroblasts are EPO target cells and respond 
to EPO treatment by activation of EPOR signaling. As men-
tioned above, in some animal studies after burns injuries,5,15 
improvement of skin wound healing and stimulation of 
neoangiogenesis was analyzed in addition to other parame-
ters, such as expression of endothelial and inducible nitric 
oxide synthases via detection of vascular endothelial growth 
factor (VEGF) wound content. However, the tissue-protective 
coexpression of EPOR and βCR in burn injury models has 
not been examined thus far. Common protein expression of 
EPOR and βCR was analyzed by Western blotting in only 
one experimental study with surgically created ventral her-
nias in pigs. This protein expression could be demonstrated 
in wound granulation tissue and wound fluids,16 but not in 
normal skin, as in our study. Our present study was designed 
as a mice scalding injury in vivo model to detect the expres-
sion of βCR in normal and scalded skin tissue and to evaluate 
the tissue protective role of rhEPO in such a condition, with 
a focus on the re-epithelialization potential of subhematopoi-
etic EPO concentrations.
Materials and methods
Animal model
The experiments were performed in adherence with the Guide 
for the Care and Use of Laboratory Animals and were 
approved by the Ethics Committee of the University of 
Lübeck. Twenty female Balb/c mice, (6–8 weeks old, body-
weight 20–25 g, Takomi, Copen  hagen, Denmark) were 
included in these experiments. The animals were kept sepa-
rately in cages under controlled environmental conditions 
and had free access to standard laboratory rodent feed and 
water ad libitum. After thermal injury, the mice were ran-
domly divided into five experimental groups of four animals 
each. In Groups 1 and 3, mice with dermal wounds received 
a daily subcutaneous 200 µL injection of 400 IU nanosize 
rhEPO/kg (NeoRecormon®, Roche Ltd, Mannheim, 
  Germany). In Groups 2 and 4, control animals with dermal 
wounds received equivalent volumes of vehicle only 
(  distilled water). The treatment duration was 7 days for 
Groups 1 and 2 and 14 days for groups 3 and 4. In addition, 
a fifth group of mice without dermal wounds served as 
  controls. EPO administration was carried out according to 
other studies in mice.15
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Scalding injury model
The animals were anesthetized with a mixture of ketamine 
hydrochloride 10 mg/kg (Bela-Pharm, Vechta, Germany) and 
xylazine 2.4 mg/kg (Bayer Health Care, Leverkusen, 
  Germany) via intraperitoneal injection; these are suitable 
anesthetic agents for inducing skin-deep second-degree scald-
ing injuries in a mouse model. After general anesthesia, the 
hair on the back was shaved and the skin washed and rinsed 
with sterile water. Creation of a second-degree scald injury 
was achieved after the area was marked with ink by a 2 × 3 cm 
window on the back of the mice and immersed in 80°C water 
for 6 seconds. Mice received 1 ml/kg saline Ringer’s solution 
immediately after scalding. The scald injury was covered with 
moist saline dressings to prevent animals from grooming. 
After thermal injury, the animals were randomized into the 
five treatment groups and received subcutaneous application 
of nanosized rhEPO or its vehicle in a blinded fashion. 
  Post-scald sedation and analgesia was provided for the first 
7 days with metamizole (1000 mg/L added to the drinking 
water). At day 7 or 14, respectively, the mice were sacrificed 
with a barbiturate overdose. The wound tissue or regenerated 
tissue was obtained for further gene expression, Western blot 
analyses, and extensive histological studies. The skin was 
excised from the scalded areas at the back of each mouse, 
divided into two segments, separately embedded, and frozen 
in liquid nitrogen as described below.
Histological analysis
All evaluations were performed on routine hematoxylin and 
eosin stainings because these enable a qualitative description 
of distinct features of the wound areas and the tissue reaction 
upon the scald trauma, and morphometric evaluation of 
distinct parameters, such as presence or absence of re- 
epithelialization, width of epidermal layer, epidermal strati-
fication, formation of rete ridges, presence of skin appendages 
(such as hair follicles), and presence of regeneration zones. 
All criteria used for histological scoring of wound healing 
are summarized in Table 1.
Gene expression analysis
After preparation of the skin samples, the RNA was obtained 
by precipitation with isopropanol. After centrifugation, the 
pellet was washed with 75% ethanol, dried, and diluted in 
RNase-free water.
RNA was purified and reverses transcribed using standard 
protocols (Qiagen, Promega, Madison, WI). Target gene prod-
ucts like EPOR (ENSMUST00000006397), βCR (ENS-
MUST00000096356),  cytokeratin  14  (CK14, 
ENSMUST00000007272), and glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH, ENSMUST00000073605, the 
housekeeping gene) were amplified by reverse transcriptase 
polymerase chain reaction using the following intron spanning 
primers: EPOR forward 5′GCGTTTCTGGTGTTCACTGC-3′ 
and reverse 5′-GGATGTGGGTGGTCATAGG-3′ (product 
length 334 base pairs, 40 cycles), βCR forward 5′- -3′ and 
reverse 5′- -3′ (product length 226 base pairs, 40 cycles), CK14 
forward 5′- -3′ and reverse 5′- -3′ (product length 306 base 
pairs, 30 cycles), Col1 forward 5′- -3′ and reverse 5′- -3′ (prod-
uct length 244 base pairs, 40 cycles), and GAPDH forward 
5′- -3′ and reverse 5′- -3′ (product length 219 base pairs, 
30 cycles).
Western blot analysis
Total protein and RNA extraction from the skin samples was 
performed using the peqGOLD Trifast method according to 
the manufacturer’s protocol (peqlab, Erlangen, Germany). 
After skin sample preparation and precipitation of protein, 
the resulting pellet was dissolved in 1% sodium dodecyl 
sulfate solution. The concentration of soluble proteins was 
determined using the bicinchoninic acid assay (Pierce, 
  Rockford, IL). We prepared the gel buffer for electrophoresis 
which comprises 120 mL and 200 mL of 1× sodium dodecyl 
sulfate buffer (prepared from 10× sodium dodecyl sulfate 
buffer, whereby 1 L contained 30 g Tris, 144 g glycine, 15 g 
sodium dodecyl sulfate) and filled the inner and lower cham-
ber of electrophoresis apparatus. We checked the assembled 
electrophoresis apparatus with water for leakage. If no leak-
Table 1 Histological scoring of wound regeneration
Score Wound closure  
(remaining wound area in %)
Score Epithelial covering
Presence Degree (mono-or 
multilayer designed)
Conical 
structure
0 75–100 0 Absence of epithel Monolayer No present
1 50–75 1 Partial reepithelialisation Partial multilayer Partial present
2 25–50
3 1–25 2 Complete reepithelialisation Multilayer Present
4 0
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Figure 1 Photographic example of the histological scoring method. The histological 
parameters of epidermal regeneration of mouse skin scored were (A) the presence 
or  absence  of  epithelial  covering,  (B)  presence  of  conical  epithelial  covering,   
and (C) degree of epithelial cell layers (monolayer or multilayer).
age is detected in 10 minutes, we removed the water. We 
inserted a filter paper to remove the remaining water from 
the electrophoresis apparatus. The wells were washed with 
sodium dodecyl sulfate buffer. The protein sample (up to 
10 µg) solved in 1× sample buffer (2× sample buffer, ie, 
2 mL 0.5 M Tris/HCl pH 6.8, 3.6 mL 86% glycerin, 0.31 g 
sodium dodecyl sulfate, 0.124 g DTT, a pinch of Bromophe-
nol blue, adjusted to 10 mL with distilled water) was heated 
at 95°C for 5 minutes. Protein samples (20 µg) were analyzed 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
in a 10% resolving gel at 120 V for one hour using the Thermo 
Scientific EC Classic Series Submarine gel system (Thermo 
Fisher Scientific, Schwerte, Germany) and visualized by the 
Coomassie brilliant blue staining method and then transferred 
by blotting to a 0.45 µm nitrocellulose membrane (Cell 
Signaling Technology, Danvers, MA) in cold transfer buffer 
(48 mM Tris pH 9, 39 mM glycine, 0,037% sodium dodecyl 
sulfate, 20% methanol). The primary antibodies against 
EPOR (sc-697), βCR, (sc-678), and growth hormone receptor 
(sc-20747) were from Santa Cruz Biotechnology (Santa Cruz, 
CA), against β-actin from Sigma (clone AC-74) and second-
ary horseradish peroxidase-conjugated antibodies (goat 
antirabbit immunoglobulin G) were from Dianova (Jackson) 
ImmunoResearch. The housekeeping β-actin signal, detected 
with secondary horseradish peroxidase-conjugated antibodies 
(goat antimouse immunoglobulin G) from Dianova, was used 
as the control for protein loading. The membranes were 
blocked with 5% nonfat dry milk in Tris-buffered saline 0.1% 
Tween-20 and 0.02% NaN3, for one hour at room   temperature. 
The immunoblots were then incubated overnight at 4°C with 
the primary antibody and for one hour with the secondary 
antibody, analyzed using an enhanced chemiluminescence 
system (Cell Signaling Technology), and exposed on a 
Molecular Imager ChemiDoc XRS system (Bio-Rad, 
  Hercules, CA). Appropriate mouse skin tissue specimens 
from the scalding experiments were freshly removed, imme-
diately embedded in TissueTec (Jung, Nussloch, Germany), 
and frozen in liquid nitrogen. Frozen tissue sections of 
10–14 µm thickness were cut on a cryotome (Leica CM 
3050 S,   Nussloch, Germany) and stained with hematoxylin 
(Mayer’s modification, Roth, Karlsruhe, Germany) and eosin 
using standard protocols.
The stainings were analyzed by light microscopy and 
images were taken on an Olympus IX 51 microscope (Olym-
pus, Tokyo, Japan) using a CC12 camera and imaging soft-
ware of the Olympus cell* family (cell* Imaging Software 
for Life Sciences Microscopy, Soft Imaging System GMbH, 
Münster, Germany). The mean values of all sections were 
allocated to the relevant score values for all individual speci-
mens and all relevant groups, and used for statistical analysis. 
The scoring data served as a reference for comparison of 
both experimental groups. The histological scoring system 
ranged between 0 and 4 for wound closure and 0 and 2 for 
each of the three partial scores of epithelial covering 
(Table 1). The score values for epithelial covering were 
summarized (up to 6) and are represented graphically 
(  Figure 2). The specimens were evaluated in parallel by two 
independent researchers, including one pathologist, in a 
blinded manner (Figure 3).
Comparable sections were evaluated every 100–200 µm 
depth at low-power (40×) and high-power magnification 
(100×). All tissue sections for each specimen ($20) were 
systematically examined using a modified histological scor-
ing system according to data in the literature.3 The histologi-
cal parameters were examined and scored as wound closure 
in the form of assessment of the remaining wound area and 
re-epithelialization (presence or absence of epithelial cover-
ing, degree of epithelial covering relative to the number of 
epithelial cell layers as a monolayer or multilayer, and pres-
ence of conical structures).
In detail, the semiquantitative score for the epithelial 
covering with the described three parameters was made by 
systematic analysis. This was done on microscopic visual 
fields of whole sections with 40× or 100× magnification of 
each specimen (Figure 1). The data for every section of the 
specimen were summarized, and the mean value was calcu-
lated and allocated to the relevant partial score value. The 
sum of the three partial score values was used as the final 
score value for each animal specimen, and was used for 
statistical analysis of the entire experimental group. We 
defined the quantitative score for wound closure to be the 
main criterion of wound healing, defined as the percentage 
of the remaining wound area when compared with the total 
skin area in the microscopic visual field of the section by 
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40× magnification. These analyses were performed on three 
random visual fields of each section.
Statistical analysis
The data for the histological scores were analyzed using the 
unpaired Student’s t-test to compare the different experimen-
tal groups. The results are expressed as the mean ± standard 
error of the mean. Statistical significance was set at 
P , 0.05.
Results
Histology
The process of wound healing was assessed during the ani-
mal’s lifetime as well as macromorphologically after sacrifice. 
The parameters of skin contraction, tissue regeneration, re-
epithelialization, shrinking of the wound area, and wound 
closure were evaluated and compared between the EPO-
treated and control groups. Markedly less skin contraction 
and considerably better skin regeneration were found as early 
as day 3 in EPO-treated mice as compared with controls. An 
overgrowth of the wound area with newly generated skin was 
observed without EPO treatment. When rhEPO was admin-
istered, examination revealed accelerated wound closure and 
re-epithelialization in contrast with controls. These findings 
were confirmed by subsequent histological evaluation.
As a first step, routine hematoxylin and eosin stainings 
7 and 14 days after the scalding trauma were systematically 
examined according to the histological score of wound 
regeneration described above (Table 1, Figure 1). The results 
of histological evaluation indicated that treatment with 
rhEPO led quantitatively and qualitatively to a visible 
improvement in wound healing with respect to wound closure 
and epithelial covering (Figure 2). Specifically, we detected 
a significant reduction of wound size in the EPO-treated 
animals, associated with faster wound closure when com-
pared with controls at day 7. In addition, an increase in 
parameters defined as “presence”, “degree”, “thickness”, and 
“re-epithelialization” of the epidermal layer was found, but 
the changes were less pronounced than those related to wound 
size. At day 14, the EPO group showed significant 
(P = 0.0129) improvement in overall wound regeneration 
for the quantitative and qualitative characteristics of 
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Figure 2 Histological scoring of the results of scald regeneration in mice treated with rhEPO or vehicle at different healing times (7 and 14 days). The final score of epithelial 
covering for each animal specimen is demonstrated as the sum of the three partial score values in Table 1.
Notes: Values are the mean ± standard error of the mean of each group. *P , 0.05 versus control group. In the EPO groups, we noticed a significant decrease in wound size 
and quicker wound closure than in the control groups at day 7. In addition, we found increased epithelial covering in the EPO treatment group than in the control group.
Abbreviations: EPO, erythropoietin; rhEPO, recombinant human erythropoietin.
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  epithelial   covering. However, the differences in wound 
closure of both groups were smaller. In the EPO-treated 
animals, there were more areas with conical structures and 
hair follicles observed than in controls. Furthermore, a 
blinded evaluation which was carried out for additional 
criteria (Figure 3) showed considerable differences between 
the EPO-treated and untreated animals in both the dermal 
and epidermal layers. These differences covered the super-
ficial defect zone, marginal epidermal regeneration, skin 
appendages, and extent and type of inflammation.
On day 7, the controls showed extensive skin defects, 
covered by inflammatory exudate, with only little   epidermal 
Control-group
a
b
c
d
e
f
EPO-group B A
Figure 3 (Continued)
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Control-group
a
b
c
d
e
f
EPO-group D C
Figure 3 representative hematoxylin and eosin stainings of scalded skin tissue samples from mice on day 7 after injury and continuous application of rhEPO or vehicle by 
subcutaneous injection. (A) Control group without EPO (vehicle only), mouse 1 (a–f); (B) EPO group, mouse 2 (a–f) on day 14; (C) control group, mouse 5 (a–f); (D) EPO 
group, mouse 8 (a–f). Magnification 40× or 100× , scale bar is 500 µm or 200 µm, respectively. In order to obtain a three-dimensional view of the wound area, each 100 µm 
thickness comparative slides were subjected to qualitative and quantitative evaluation. All evaluations were performed on hematoxylin and eosin routine stainings. The 
following histological parameters were examined and scored: wound closure in the form of assessment of remaining wound area and re-epithelialization (presence or 
absence of epithelial covering, degree of epithelial covering relative to number of epithelial cell layers as monolayer or multilayer designed, presence of conical structures). 
All criteria used for histological scoring of wound healing are summarized in Table 1. In order to render the observations comparable, sections every 100–200 µm in depth 
were evaluated at low-power (40×) and high-power magnification (100×). 
Notes: a–f: from a to b; b to c: c to d; d to e; e to f is a 100–200 µm distance of the cryosection.
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cell proliferation at the defect margins. The skin 
  appendages, mainly hair follicles, showed significant 
necrosis or at least major necrobiosis, as evidenced by 
enhanced apoptotic cell changes. In the central areas of 
the defect zone, the skin appendages were completely lost. 
Furthermore, the controls showed strong inflammation with 
mixed granulocyte-lymphocyte infiltration accumulated at 
the defect interface, while early granulation tissue was seen 
at the marginal zone.
Simultaneously, the rhEPO-treated animals showed 
enhanced epidermal regeneration with a hyperplastic epider-
mis, moderately sized defect formation, and also moderately 
expressed mixed inflammation in contrast with the controls. 
Skin appendages were necrobiotic in the control group 
(  Figure 3). Fourteen days after scalding, the controls 
  demonstrated partial coverage of the defects by epidermis; 
skin appendages were slightly regenerating and a strong 
lymphocytic inflammation was present.
Finally, rhEPO-treated animals showed nearly complete 
covering of the defect zone by broadened regenerating epi-
dermis along with strong regeneration of the hair follicles. 
The extent of inflammation was smaller than in the controls 
(Figure 3). The control animals showed less extensive recov-
ery of the epidermis and lower levels of re-epithelialization 
at both assessments (day 7 and day 14). These results suggest 
that administration of rhEPO led to accelerated wound 
  closure and re-epithelialization as well as skin regeneration. 
The results of this study suggest the potential efficacy of a 
subcutaneous EPO injection in accelerating skin regeneration 
following scalding injuries.
Gene expression
The data presented here show common expression and 
upregulation of EPOR-βCR in scalded skin during the healing 
process (Figure 4A). The qualitative and quantitative differ-
ences in healing of scalding wounds between the experimen-
tal groups could only be evaluated by the histological score 
(Figure 1), where we found major differences. Impaired 
wound healing in the scalds in relation to wound closure (as 
the main criteria) described above was found in control mice 
when compared with EPO-treated mice. Furthermore, the 
quality of the newly formed epithelial covering in the control 
mice had not improved, even after an extended healing 
period. In comparison, we found significantly better wound 
closure (P = 0.0311 at day 7) and quality of re-  epithelialization 
(P = 0.0129 at day 14) in the EPO-treated mice.
The tissue-protective heterodimer receptor is induced in 
the case of wounding under hypoxic conditions. However, we 
found common EPOR-βCR expression also in uninjured skin. 
According to our previous findings and the evidence of 
Bodó et al,8 normal human skin expresses EPO and functional 
EPOR in situ, and human scalp hair follicles are important 
extrarenal sources and extrahematopoietic targets of EPO- 
induced signaling. In contrast with the EPOR expression 
described for injured skin samples and nonscalded skin controls, 
we found that application of EPO caused a downregulation of 
EPOR expression in the healthy nonscalded mouse (Figure 4A). 
This result was consistent with our previous findings.
Protein expression
We investigated protein expression in the tissue-protective 
EPO receptor, characterized by the heterodimer isoform in 
combination with βCR, and found slight expression of both 
receptors in the majority of samples (lower for βCR due to 
the deficient antibody reaction, Figure 4B), which confirms 
the results of our gene expression analysis. Due to some 
loading problems, the expression of β actin was very negli-
gible in 7–10 of the samples.
In these analyses, we used the antimouse EPOR antibody 
M-20 from Santa Cruz Biotechnology. Elliott et al19 exam-
ined the specificity of common available anti-EPOR 
antibodies used in the immunoblotting and immunohis-
tochemical analyses of various investigators, and demon-
strated that almost all antibodies have limited utility for 
detecting EPOR because of cross-reactivity with non-EPOR 
proteins. They concluded that M-20 alone was suitable for 
detection of EPOR in Western blots, so we used the same 
in our present study.
Discussion
Normally in skin injuries, EPO is locally produced in a non-
hematopoietic manner, and is an effective natural way to 
achieve adequate wound healing of the injury site, even 
without any medication. However, a condition such as a 
second-degree scalding injury involves healing processes 
additional to those for less traumatic skin injuries, where 
tissue ischemia may contribute to increased endogenous 
production of EPO, both locally and systemically. In extensive 
wound situations, there is a systemic and probably local 
deficiency of EPO. More important is the fact that a deep 
second-degree burn is accompanied by destruction of the 
entire epidermis and also partially the dermal skin structures 
along with the stem cells contained therein, which causes 
impaired wound healing and decreased local synthesis of 
EPO, characterized by delayed formation of granulation tis-
sue, decreased deposition of collagen, and angiogenesis.
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This results in large-scale reduction of stem cell numbers in 
the basal layer, of the hair follicle structures, and of the dermis, 
which might be directly related to EPO synthesis and its tissue-
protective function. Bodó et al8 have previously reported on 
immunohistological and RNA expression of EPO and EPOR 
transcripts in the outer root sheath stem cells of the hair follicle 
and further on EPOR expression in human dermally derived 
fetal mesenchymal stem cells.6 Therefore, it might be a promis-
ing approach to restore the deficiency of EPO using an exoge-
nous supply to enhance healing of dermal thermal injuries.
EPO is a cytokine that has received great attention in the 
context of wound repair by topical or systemic application 
in animals as well as in acute and chronic wounds in 
humans.5,6 So far, no publications could be found concerning 
the coexpression of βCR in addition to EPOR in dermal 
thermal injuries. Here we describe for the first time RNA 
expression of βCR during scald healing and report our results 
for the detection of EPOR and βCR expression in deep 
second-degree scalds (Figure 4A). Receptor expression was 
independent of EPO administration. The EPOR expression 
level varied between the experimental groups in this study, 
but did not show a distinct relationship with EPO treatment 
(Figure 4A). EPOR and βCR expression could only be 
determined semiquantitatively but not immunohis-
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Figure 4 Analysis of gene and protein expression of EPOr, βCr, and growth hormone receptor. (A) reverse transcriptase polymerase chain reaction analysis of gene 
expression of EPOr, βCr, and growth hormone receptor, and characteristic markers of scalded mouse skin tissue samples on days 7 and 14 after injury and continuous 
application of rhEPO or its vehicle (control) by subcutaneous injection. DNA bands 1–4 scalded mice of EPO group (+EPO) on day 7; bands 5–8, scalded mice of control 
group (-EPO, vehicle) on day 7; band 9, nonscalded mouse with EPO application (control); band 10, nonscalded mouse without EPO application (control) on day 7; bands 
11–14, scalded mice of EPO group (+EPO) on day 14; bands 15–16, scalded mice of control group (-EPO, vehicle) on day 14; bands 17–19, three additional tissues as 
comparable controls; band 17, skin nonscalded control; band 18, spleen nonscalded control; band 19, kidney nonscalded control. Polymerase chain reaction products for 
EPOr, βCr, and other markers were visualized on 1.5% agarose gel with ethidium bromide. (B) Western blot analysis of protein expression of EPOr, βCr, and growth 
hormone receptor of scalded skin tissue samples of mice on days 7 and 14 after injury and continuous application of rhEPO or its vehicle (control) by subcutaneous injection. 
Bands 1–4, mice of EPO group (+EPO) on day 7; bands 5–8, mice of control group (EPO, vehicle) on day 7; band 9, nonscalded mouse with EPO application (control); band 
10, nonscalded mouse without EPO application (control) on day 7; bands 11–14, mice of EPO group (+EPO) on day 14; bands 15–16, mice of control group (-EPO, vehicle) 
on day 14; band 17, additional mouse liver tissue as nonscalded comparable control (-EPO). β-actin was used as loading control. 
Abbreviations: EPO, erythropoietin; rhEPO, recombinant human erythropoietin; EPOr, erythropoietin receptor; βCr, common β subunit receptor.
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tochemically with respect to localization of EPO-synthesizing 
structures, probably due to a well known deficient antibody 
reaction.19
We have previously demonstrated that EPO has an inhibi-
tory effect on skin cells and stem cells in the normal 
(“healthy”) environment, but the presence of inflammatory 
cytokines in the case of hypoxic skin conditions changes the 
function of EPO to one of stimulating stem cell proliferation 
and differentiation.6,17 We were able to confirm this inhibitory 
effect of EPO by the above-described gene and protein 
expression results. Herndon et al18 investigated growth hor-
mone enhancement for re-epithelialization in burns patients 
and concluded that growth hormone affects wound healing 
and tissue repair. An aspect of interest is the fact that we 
found RNA expression of the growth hormone receptor in 
both intact and injured skin (  Figure 4A). In addition to the 
findings of Bodó et al,8 our present results concerning the 
tissue-protective role of EPO support the hypotheses about 
the intracutaneous functions of EPO and the potential role 
of the skin in the control of EPO production or upregulation 
in response to hypoxia.20 EPO seems most likely to be a 
modulator between stem cells and the tissue response, leading 
to site-specific tissue formation in response to trauma. As a 
result of our study, we assume that mouse skin stem cells as 
well as human skin stem cells are the specific responsive 
elements in uninjured skin containing the heterodimeric EPO 
receptor and thus show a special readiness for action in the 
event of traumatic skin injuries, especially thermal trauma.
Recent encouraging evidence suggests that nanosized 
PEGylated EPO has remarkable advantages over rhEPO.21 
Nanosized EPO31-PEG has a five-fold longer terminal half-
life and similar biologic activity to that of unmodified rhEPO. 
The extended terminal half-life of rhEPO confers longer 
therapeutic benefits, but there is an increased risk of systemic 
complications with such a long terminal half-life. Generally 
the half-life of EPO in plasma is only around 5 hours. We 
preferred to inject rhEPO with its short half-life in patients 
with local burns injuries so that rhEPO can be degraded by 
protease without the risk of systemic complications. rhEPO 
is a nanosized drug because rhEPO is a nanosized highly 
glycosylated protein comprising 165 amino acids. It has been 
reported about the three-dimensional structure of other 
derivatives of rhEPO such as MKLs EPO shows the protein 
is 25Å×35Å×47Å.22
The potential role of a single intraperitoneal injection of 
EPO-loaded oligochitosan nanoparticles has been   investigated 
for the treatment for periventricular leukomalacia, and the 
average diameter of the EPO nanoparticles was 266 nm.23 
EPO-loaded oligochitosan nanoparticles were designed to 
protect EPO from protease digestion and prolong the treat-
ment effect in periventricular leukomalacia by controlling 
and prolonging the release of EPO. Meloxicam-loaded 
Eudragit EPO nanoparticles have a particle size of approxi-
mately 100 nm.24 Herein, to the best of our knowledge, we 
show for the first time by both gene and protein expression 
that normal and scalded skin belong to the tissues that recruit 
the EPOR/βCR system for tissue protection and that they are 
an extrahematopoietic site of EPOR expression.
Conclusion
We examined tissue protection as well as skin regeneration 
via coexpression of EPOR and βCR in a burns injury model. 
Complete skin regeneration with conical and hair follicle 
structure at the burned injury site occurred upon local nano-
sized rhEPO injection. This finding has important clinical 
implications with regard to the potential use of local subcu-
taneous injection at the injury site in burns patients. 
  Additionally, we speculated that coexpression of EPOR and 
βCR constitutes a tissue protective heteroreceptor in the scald 
healing process. We investigated the role of nanosized rhEPO 
in tissue regeneration of scalds for the first time by expression 
of tissue-protective EPOR, characterized as the heterodimer 
isoform in combination with the βCR on mRNA as well as 
at protein level. The concept of local subcutaneous injection 
of rhEPO might be beneficial for prevention and treatment 
of moderate to severe post-burn patients for complete skin 
regeneration with conical and hair follicle structure.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response 
to severe burn injury. Ann Surg. 2008;248:387–401.
2.  Avni T, Levcovich A, Ad-El DD, Leibovici L, Paul M. Prophylactic 
antibiotics for burns patients: systematic review and meta-analysis. BMJ. 
2010;340:c241.
3.  Galeano M, Altavilla D, Cucinotta D, et al. Recombinant human eryth-
ropoietin stimulates angiogenesis and wound healing in the genetically 
diabetic mouse. Diabetes. 2004;53:2509–2517.
4.  Sorg H, Krueger C, Schulz T, Menger MD, Schmitz F, Vollmar B. Effects 
of erythropoietin in skin wound healing are dose related. FASEB J. 
2009;23:3049–3058.
5.  Hamed S, Ullmann Y, Masoud M, Hellou E, Khamaysi Z, Teot L. Topical 
erythropoietin promotes wound repair in diabetic rats. J Invest Dermatol. 
2010;130:287–294.
6.  Bader A, Lorenz K, Richter A, et al. Interactive role of trauma cytokines 
and erythropoietin and their therapeutic potential for acute and chronic 
wounds. Rejuvenation Res. 2011;14:57–66.
7.  Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signalling 
through a variety of cytokine receptors. Cell. 1998;93:385–395.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1236
Bader et alInternational Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology in 
diagnostics, therapeutics, and drug delivery systems throughout the 
biomedical field. This journal is indexed on PubMed Central, MedLine, 
CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal 
Citation Reports/Science Edition, EMBase, Scopus and the Elsevier 
Bibliographic databases. The manuscript management system is 
completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2012:7
  8.  Bodó E, Kromminga A, Funk W, et al. Human hair follicles are an 
extrarenal source and a nonhematopoietic target of erythropoietin. 
FASEB J. 2007;21:3346–3354.
  9.  Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004; 
8:649–659.
  10.  Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue 
protection through an erythropoietin and common beta-subunit heter-
oreceptor. Proc Natl Acad Sci U S A. 2004;101:14907–14912.
  11.  Brines M, Cerami A. Erythropoietin mediated tissue protection: reduc-
ing collateral damage from the primary injury response. J Intern Med. 
2008;264:405–432.
  12.  Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin 
receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008; 
67:39–61.
  13.  Scott CL, Robb L, Papaevangeliou B, Mansfield R, Nicola NA, 
  Begley CG. Reassessment of interactions between hematopoietic recep-
tors using common beta-chain and interleukin-3-specific receptor 
beta-chain-null cells: no evidence of functional interactions with recep-
tors for erythropoietin, granulocyte colony stimulating factor, or stem 
cell factor. Blood. 2000;96:1588–1590.
  14.  LeBaron MJ, Ahonen TJ, Nevalainen MT, Rui H. In vivo response-
based identification of direct hormone target cell populations using 
high-density tissue arrays. Endocrinology. 2007;148:989–1008.
  15.  Galeano M, Altavilla D, Bitto A, et al. Recombinant human erythro-
poietin improves angiogenesis and wound healing in experimental burn 
wounds. Crit Care Med. 2006;34:1139–1146.
  16.  Saqib N, Dulin L, Krier K, Howdieshell TR. Temporal and spatial 
expression of erythropoietin, erythropoietin receptor, and common β 
receptor in wound fluid and granulation. Wounds. 2009;21:7.
  17.  Lorenz K, Sicker M, Schmelzer E, et al. Multilineage differentiation 
potential of human dermal skin-derived fibroblasts. Exp Dermatol. 
2008;11:925–932.
  18.  Herndon DN, Hawkins HK, Nguyen TT, Pierre E, Cox R, Barrow RE. 
Characterization of growth hormone enhanced donor site healing in 
patients with large cutaneous burns. Ann Surg. 1995;221:649–656.
  19.  Elliott S, Busse L, Bass MB. Anti-Epo receptor antibodies do not predict 
Epo receptor expression. Blood. 2006;107:1892–1895.
  20.  Paus R, Bodó E, Kromminga A, Jelkmann W. Erythropoietin and the 
skin: a role for epidermal oxygen sensing? Bioessays. 2009;31: 
344–348.
  21.  Cohan RA, Madadkar-Sobhani A, Khanahmad H, et al. Design, model-
ing, expression, and chemoselective PEGylation of a new nanosize 
cysteine analog of erythropoietin. Int J Nanomedicine. 2011;6: 
1217–1227.
  22.  Cheetham JC, Smith DM, Aoki KH, et al. NMR structure of human 
erythropoietin and a comparison with its receptor bound conformation. 
Nat Struct Biol. 1998;5:861–866.
  23.  Wang T, Hu Y, Leach MK, et al. Erythropoietin-loaded oligochitosan 
nanoparticles for treatment of periventricular leukomalacia. Int J Pharm. 
2012;422:462–471.
  24.  Khachane P, Date AA, Nagarsenker MS. Eudragit EPO nanoparticles: 
application in improving therapeutic efficacy and reducing ulcerogenic-
ity of meloxicam on oral administration. J Biomed Nanotechnol. 2011; 
7:590–597.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1237
Skin regeneration with nanosized rhEPO